Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Shineway Pharmaceutical GroupCSWYY 86 3-Year EBITDA Growth Rate is 6.50% as of Dec. 2025, which is 7% above its 10-year median of 6.05. GuruFocus rates CSWYY with a GF Score™ of 86/100 and a GF Value™ of $15.55. The stock has 2 warning signs investors should review. Among 815 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks worse than 53.62% on this metric.
During the past 12 months, China Shineway Pharmaceutical Group's average EBITDA Per Share Growth Rate was 14.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Shineway Pharmaceutical Group was 42.30% per year. The lowest was -17.70% per year. And the median was 6.05% per year.
China Shineway Pharmaceutical Group (OTCPK:CSWYY) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
China Shineway Pharmaceutical Group 3-Year EBITDA Growth Rate Related Terms
CSWYY vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's 3-Year EBITDA Growth Rate falls into.
China Shineway Pharmaceutical Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.50% mean?
China Shineway Pharmaceutical Group (CSWYY) has a 3-Year EBITDA Growth Rate of 6.50% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for China Shineway Pharmaceutical Group and its competitors. This is near median its historical median of 6.05. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #437 out of 815 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is China Shineway Pharmaceutical Group's 3-Year EBITDA Growth Rate too high?
China Shineway Pharmaceutical Group's current 3-Year EBITDA Growth Rate of 6.50% is near median its 10-year median of 6.05. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. China Shineway Pharmaceutical Group's value of 6.50% is 26.1% below this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #437 out of 815 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #437 out of 815 companies for 3-Year EBITDA Growth Rate. This places China Shineway Pharmaceutical Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. China Shineway Pharmaceutical Group's value of 6.50% is 26.1% below this benchmark. While the company's 10-year median is 6.05 vs. the industry median of 8.80, China Shineway Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current 3-Year EBITDA Growth Rate of 6.50% is 26.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current 3-Year EBITDA Growth Rate is 6.50%, which is near median its own 10-year median of 6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current 3-Year EBITDA Growth Rate of 6.50%. The stock's GF Value™ is $15.55, compared to a current price of $19.25 — trading 23.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.50%, which is near median its 10-year median of 6.05 and 26.1% below the Drug Manufacturers industry median of 8.80. China Shineway Pharmaceutical Group's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current 3-Year EBITDA Growth Rate is 6.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 23.8% above its estimated GF Value™ of $15.55.
Key valuation signals for CSWYY:
3-Year EBITDA Growth Rate: 6.50% (near median its 10-year median of 6.05)
GF Value™: $15.55 vs. price of $19.25 (23.8% above fair value)
Industry Position: 26.1% below the Drug Manufacturers median (#437 of 815)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
86GF Score
Get the complete analysis for CSWYY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
